Systemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Mar 14, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a specific biological process called inflammasome activation might be linked to frailty in older adults who are candidates for kidney transplantation. Frailty is a condition that can make people more vulnerable to complications after surgery, and researchers want to understand if inflammation plays a role in this. By studying older patients with chronic kidney failure, the trial hopes to find out if there is a connection between frailty and inflammation, which could help improve care for these patients.
To be eligible for this study, participants need to be at least 70 years old and currently being evaluated for kidney transplantation. They should not have any major health issues that would prevent them from participating and must provide written consent to join the study. Participants can expect to undergo some assessments related to their health and frailty during the trial. It’s important to note that this study is not yet recruiting participants, so those interested will need to wait for the enrollment to begin.
Gender
ALL
Eligibility criteria
- * Inclusion criteria:
- • Age ≥ 70
- • Patient candidate to kidney transplantation (during assessment for inscription on the waiting-list, or during waiting time after effective inscription), without absolute contraindication
- • Free, informed and written consent signed by the participant and the investigator (at the latest, on the day of inclusion and before any examination required by the research).
- • Person affiliated or beneficiary of a social security scheme
- * Exclusion criteria:
- • Inclusion in an industrial study refusing co-inclusion in our study
- • Person under guardianship, assisted decision-making or under temporary guardianship
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Bordeaux, , France
Pessac, , France
Patients applied
Trial Officials
Florent GUERVILLE, MD
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported